Managing chronic hepatitis C in the difficult-to-treat patient.

Managing chronic hepatitis C in the difficult-to-treat patient. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Managing chronic hepatitis C in the difficult-to-treat patient. Abstract Text:

Nyingi Kemmer,Guy W Neff,Nyingi Kemmer,Guy W Neff,Nyingi Kemmer,Guy W Neff,

Patients with chronic hepatitis C virus (HCV) infection and disease-related complications - among them cirrhosis and liver failure - pose a particular management challenge. Some of these patients may fail to respond to current therapy (non-responders), and some are affected so severely that treatment puts them at an unacceptable risk for complications. Treatment with pegylated interferon (peg-IFN) plus ribavirin improves hepatic enzyme levels and eradicates the virus in approximately 50% of patients; however, a significant number of patients do not respond to therapy or relapse following treatment discontinuation. Several viral, hepatic and patient-related factors influence response to IFN therapy; many of these factors cannot be modified to improve long-term outcomes. Identifying risk factors and measuring viral load early in the treatment can help to predict response to IFN therapy and determine the need to modify or discontinue treatment. Retreatment options for patients who have failed therapy are limited. Retreatment with peg-IFN has been successful in some patients who exhibit an inadequate response to conventional IFN treatment, particularly those who have relapsed. Consensus IFN, another option in treatment-resistant patients, has demonstrated efficacy in the retreatment of non-responders and relapsers. Although the optimal duration of retreatment and the benefits and safety of maintenance therapy have not been determined, an extended duration is likely needed. This article reviews the risk factors for HCV treatment resistance and discusses the assessment and management of difficult-to-treat patients.

Managing chronic hepatitis C in the difficult-to-treat patient. Publishing Authors By Initials

N Kemmer,GW Neff,N Kemmer,GW Neff,N Kemmer,GW Neff,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Managing chronic hepatitis C in the difficult-to-treat patient. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Liver international : official journal of the Inte

VOLUME: 27

Page Numbers: 1297-310

Journal Abbreviation: Liver Int.

ISSN: 1478-3223

DAY: 26

MONTH: Dec

YEAR: 2007

Managing chronic hepatitis C in the difficult-to-treat patient. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101160857

Managing chronic hepatitis C in the difficult-to-treat patient. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Managing chronic hepatitis C in the difficult-to-treat patient. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Managing chronic hepatitis C in the difficult-to-treat patient.

AFFILIATION: Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, OH, USA.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Liver Int

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Managing chronic hepatitis C in the difficult-to-treat patient Related Publications

• A hierarchical approach measures the aerial extent and concentration levels of PAH-contaminated shoreline sediments at historic industrial sites in Prince William Sound, Alaska.
• ADDRESS OF THE CHAIRMAN OF THE MUNICIPAL HEALTH OFFICERS' SECTION.
• Antiviral chemotherapy; flavones and related compounds.
• Antiviral chemotherapy; further trials.
• Bifid tail of the pancreas: benign bifurcation anomaly.
• Congenital pyloric stenosis.
• Demonstration of a false aneurysm of the extremity by dynamic radionuclide scintigraphy.
• Early mammographic and sonographic findings after intraoperative radiotherapy (IORT) as a boost in patients with breast cancer.
• Effects of masker-spectral variability and masker fringes in children and adults.
• Estimates of CO2 from fires in the United States: implications for carbon management.
• Immune thrombocytopenia from vancomycin in orthopedic cement.
• Impact of geographic location on access to liver transplantation among ethnic minorities.
• Intestinal schistosomiasis following orthotopic liver transplantation: a case report.
• Managing chronic hepatitis C in the difficult-to-treat patient.
• Parosteal osteosarcoma.
• RECENT PUBLIC HEALTH WORK IN THE UNITED STATES ESPECIALLY IN RELATION TO INFANT MORTALITY.
• Regional cerebral blood flow and blood volume in patients with subcortical arteriosclerotic encephalopathy (SAE).
• Reliability and Validity of MR Image Lung Volume Measurement in Fetuses with Congenital Diaphragmatic Hernia and in Vitro Lung Models.
• Revisiting posttransplant survival for hepatitis C virus recipients.
• Role of the Voluntary Agency in the Overall Health Program.
• Role of the voluntary agency in the overall health program.
• Steroid hormones in bluegill, a species with male alternative reproductive tactics including female mimicry.
• Tailored occlusion with the anterior coefficient.
• Tracking health and the environment: a pilot test of environmental public health indicators.
• [An apparatus for technical improvement of oxygen therapy.]
• [Effect of BC 105 on the depressed mood in migraine]
• [Not Available.]
• [Observations on the problem of therapy of coxarthrosis.]
• [Prevention of osteoporosis]
• [The surgical treatment of coxarthrosis.]